van Gennip April C E, Schram Miranda T, Köhler Sebastian, Kroon Abraham A, Koster Annemarie, Eussen Simone J P M, de Galan Bastiaan E, van Sloten Thomas T, Stehouwer Coen D A
Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, Netherlands; School for Cardiovascular Diseases CARIM, Maastricht University, Maastricht, Netherlands.
Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, Netherlands; Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, Netherlands; School for Cardiovascular Diseases CARIM, Maastricht University, Maastricht, Netherlands; School for Mental Health and Neuroscience MHENS, Maastricht University, Maastricht, Netherlands.
Lancet Healthy Longev. 2023 Feb;4(2):e63-e71. doi: 10.1016/S2666-7568(22)00291-4.
Type 2 diabetes is associated with an increased risk of depression, but the extent to which risk factor modification can mitigate this risk is unclear. We aimed to examine the association between the incidence of major depression and clinically relevant depressive symptoms among individuals with type 2 diabetes, according to the number of risk factors within the recommended target range, compared with individuals without diabetes.
We did a prospective analysis of population-based data from the UK Biobank and the Maastricht Study. Individuals with type 2 diabetes were categorised according to the number of risk factors within the recommended target range (non-smoking, guideline-recommended levels of glycated haemoglobin (HbA), blood pressure, BMI, albuminuria, physical activity, and diet). The primary outcome, based on data from the UK Biobank, was the incidence of major depression ascertained from hospital records; the secondary outcome, based on data from the UK Biobank and the Maastricht Study, was clinically relevant depressive symptoms based on a score of 10 or higher on the Patient Health Questionnaire (PHQ-9).
The study population of the UK Biobank comprised 77 786 individuals (9047 with type 2 diabetes and 68 739 without diabetes; median age 59 years [IQR 51-64]; 34 136 [43·9%] women and 43 650 [56·1%] men). A median of 12·7 years (IQR 11·8-13·4) after recruitment (between March 13, 2006, and Oct 1, 2010), 493 (5·5%) of 9047 individuals with type 2 diabetes and 2574 (3·7%) of 68 739 individuals without diabetes developed major depression. Compared with individuals without diabetes, those with type 2 diabetes had a higher risk of major depression (hazard ratio [HR] 1·61 [95% CI 1·49-1·77]). Among individuals with type 2 diabetes, the excess risk of depression decreased stepwise with an increasing number of risk factors within the recommended target range (HR 2·04 [95% CI 1·65-2·52] for up to two risk factors within the recommended target range; 1·95 [1·65-2·30] for three risk factors within the recommended target range; 1·38 [1·16-1·65] for four risk factors within the recommended target range; and 1·34 [1·12-1·62] for five to seven risk factors within the recommended target range). In the UK Biobank dataset, a median of 7·5 years (IQR 6·8-8·2) after the baseline examination, 147 (7·5%) of 1953 individuals with type 2 diabetes and 954 (4·5%) of 21 413 individuals without diabetes had developed clinically relevant depressive symptoms. The study population of the Maastricht Study comprised 4530 individuals (1158 with type 2 diabetes and 3372 without diabetes; median age 60 years [IQR 53-66]; 2244 [49·5%] women and 2286 [50·1%] men). A median of 5·1 years (IQR 4·1-6·1) after recruitment (between Sept 1, 2010, and Dec 7, 2017), 170 (14·7%) of 1158 individuals with type 2 diabetes and 227 (6·7%) of 3372 individuals without diabetes developed clinically relevant depressive symptoms. Similarly, in both the UK Biobank dataset and the Maastricht Study cohort, among individuals with type 2 diabetes, the excess risk of clinically relevant depressive symptoms decreased stepwise with an increasing number of risk factors within the recommended target range.
Among individuals with type 2 diabetes, the excess risk of major depression and clinically relevant depressive symptoms decreased stepwise with an increasing number of risk factors within the recommended target range. This study provides further evidence to promote risk factor modification strategies in individuals with type 2 diabetes and to encourage the adoption of a healthy lifestyle.
ZonMW, Hartstichting, and Diabetes Fonds.
2型糖尿病与抑郁症风险增加相关,但风险因素调整能在多大程度上减轻这种风险尚不清楚。我们旨在根据推荐目标范围内的风险因素数量,研究2型糖尿病患者中重度抑郁症的发病率和临床相关抑郁症状之间的关联,并与非糖尿病患者进行比较。
我们对来自英国生物银行和马斯特里赫特研究的基于人群的数据进行了前瞻性分析。2型糖尿病患者根据推荐目标范围内的风险因素数量(不吸烟、糖化血红蛋白(HbA)、血压、体重指数、蛋白尿、身体活动和饮食的指南推荐水平)进行分类。基于英国生物银行的数据,主要结局是从医院记录中确定的重度抑郁症发病率;基于英国生物银行和马斯特里赫特研究的数据,次要结局是根据患者健康问卷(PHQ-9)得分10分及以上确定的临床相关抑郁症状。
英国生物银行的研究人群包括77786人(9047例2型糖尿病患者和68739例非糖尿病患者;中位年龄59岁[四分位间距51-64];34136名[43.9%]女性和43650名[56.1%]男性)。在招募后(2006年3月13日至2010年10月1日)中位12.7年(四分位间距11.8-13.4)时,9047例2型糖尿病患者中有493例(5.5%)发生重度抑郁症,68739例非糖尿病患者中有2574例(3.7%)发生重度抑郁症。与非糖尿病患者相比,2型糖尿病患者发生重度抑郁症的风险更高(风险比[HR]1.61[95%CI1.49-1.77])。在2型糖尿病患者中,随着推荐目标范围内风险因素数量的增加,抑郁症的额外风险逐步降低(推荐目标范围内最多两个风险因素时HR2.04[95%CI1.65-2.52];推荐目标范围内三个风险因素时HR1.95[1.65-2.30];推荐目标范围内四个风险因素时HR1.38[1.16-1.65];推荐目标范围内五至七个风险因素时HR1.34[1.12-1.62])。在英国生物银行数据集中,基线检查后中位7.5年(四分位间距6.8-8.2)时,1953例2型糖尿病患者中有147例(7.5%)出现临床相关抑郁症状,21413例非糖尿病患者中有954例(4.5%)出现临床相关抑郁症状。马斯特里赫特研究的研究人群包括4,530人(1,158例2型糖尿病患者和3,372例非糖尿病患者;中位年龄60岁[四分位间距53-66];2,244名[49.5%]女性和2,286名[50.1%]男性)。在招募后(2010年9月1日至2017年12月7日)中位5.1年(四分位间距4.1-6.1)时,1158例2型糖尿病患者中有170例(14.7%)出现临床相关抑郁症状,3372例非糖尿病患者中有227例(6.7%)出现临床相关抑郁症状。同样,在英国生物银行数据集和马斯特里赫特研究队列中,2型糖尿病患者中,随着推荐目标范围内风险因素数量的增加,临床相关抑郁症状的额外风险逐步降低。
在2型糖尿病患者中,随着推荐目标范围内风险因素数量的增加,重度抑郁症和临床相关抑郁症状的额外风险逐步降低。本研究提供了进一步的证据,以促进2型糖尿病患者的风险因素调整策略,并鼓励采用健康的生活方式。
荷兰卫生与福利研究所、心脏病基金会和糖尿病基金会。